Key takeaways: Alkermes will acquire Avadel for $18.50 per share, plus a potential $1.50 contingent payment tied to LUMRYZ’s FDA…
Tag: Alkermes
Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study
Summary: Alkermes’ alixorexton met all primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing…
The Race Toward Orexin Agonists Targeting Narcolepsy’s Root Cause
By Alyx Arnett For the first time, investigational treatments for narcolepsy type 1 (NT1) are targeting the disorder’s root cause:…